The introduction of CT Eye and MSK Eye represents Oxipit’s evolution from a chest X- ray AI pioneer into a broader multi-modality radiology AI provider and marks the first step toward extending Oxipit’s vision of autonomous radiology into new imaging modalities beyond chest X-ray. CT Eye launches with three critical chest CT findings, with additional indications already in development as part of the CT Eye roadmap.
More information about CT Eye and MSK Eye is available at www.oxipit.ai.
Ad Statistics
Times Displayed: 28836
Times Visited: 68 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money.
About Oxipit
Founded in 2017 by experts in medicine and data science, Oxipit is a leader in AI-based medical imaging. The company introduced ChestEye in 2019 for detection of 75 chest X-ray findings and launched ChestLink in 2022 as the world’s first CE Class IIb certified solution capable of identifying normal chest X-rays with 99.9% sensitivity. In 2026, Oxipit expanded its portfolio into chest CT and musculoskeletal X-ray imaging, continuing to support radiologists through workflow-integrated detection, prioritisation, and reporting support in daily clinical practice worldwide.
Back to HCB News
